[1] XIE Y,BOWE B,MOKDAD A H,et al.Analysis of the Global Burden of Disease study highlights the global,regional,and national trends of chronic kidney disease epidemiology from 1990 to 2016[J]. Kidney Int,2018,94(3):567-581.
[2] STOLIC R.Most important chronic complications of arteriovenous fistulas for hemodialysis[J]. Med Princ Pract,2013,22(3):220-228.
[3] AKIN D,OZMEN S,KAYA R.A novel factor for prim ry arteriovenous fistula failure:hyperinsulinism[J]. Ren Fail,2016,38(8):1206-1209.
[4] ALTUN B,ARICI M,HAZNEDAROĞLU I C,et al. Serum thrombopoietin levels in haemodialysis patients:involvement of arteriovenous fistula[J]. Nephrol Dial Transplant,1999,14(9):2173-2177.
[5] STRACKE S,KONNER K,KÖSTLIN I,et al. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas[J]. Kidney Int,2002,61(3):1011-1019.
[6] WEISS M F,SCIVITTARO V,ANDERSON J M.Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access[J]. Am J Kidney Dis,2001,37(5):970-980.
[7] ROY-CHAUDHURY P,SUKHATME V P,CHEUNG A K.Hemodialysis vascular access dysfunction:a cellular and molecular viewpoint[J]. J Am Soc Nephrol,2006,17(4):1112-1127.
[8] LU F P,LIU L P,LU Z X.One-year patency rate of native arteriovenous fistulas reconstructed by vascular stripping in hemodialysis patients with venous neointimal hyperplasia[J]. J Vasc Surg,2015,61(1):192-196.
[9] AKIMOTO T,KUSANO E,FUJITA N,et al.Erythropoietin modulates angiotensin II-or noradrenaline-induced Ca(2+) mobilization in cultured rat vascular smooth-muscle cells[J]. Nephrol Dial Transplant,2001,16(3):491-499.
[10] JANMAAT M L,HEERKENS J L T,DE BRUIN A M,et al. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release[J]. Blood,2010,115(7):1453-1460.
[11] RAYNER H C,PISONI R L.Opinion:the increasing use of hemodialysis catheters:evidence from the DOPPS on its significance and ways to reverse it[J]. Semin Dial,2010,23(1):6-10.
[12] Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access[J]. Am J Kidney Dis, 2006, 48(Suppl 1): S176-247.
[13] 金海姣,倪兆慧. 血液透析血管通路的临床应用现状分析[J]. 中国血液净化,2016,15(1):39-41.
[14] 黄玲,彭小梅. 动静脉内瘘狭窄及血栓形成的危险因素及预防[J]. 内科,2017,12(3):332-333.
[15] GRANDALIANO G,TEUTONICO A,ALLEGRETTI A,et al.The role of hyperparathyroidism,erythropoietin therapy,and CMV infection in the failure of arteriovenous fistula in hemodialysis[J]. Kidney Int,2003,64(2):715-719.
[16] ROOZBEH J,SERATI A R,MALEKHOSEINI S A.Arteriovenous fistula thrombosis in patients on regular hemodialysis:a report of 171 patients[J]. Arch Iran Med,2006,9(1):26-32.
[17] DE MARCHI S,CECCHIN E,FALLETI E,et al.Long-term effects of erythropoietin therapy on fistula Stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients[J]. J Am Soc Nephrol,1997,8(7):1147-1156.
[18] AMMARGUELLAT F,GOGUSEV J,DRÜEKE T B. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor[J]. Nephrol Dial Transplant,1996,11(4):687-692.
[19] DASHKEVICH A,HAGL C,BEYERSDORF F,et al.VEGF pathways in the lymphatics of healthy and diseased heart[J]. Microcirculation,2016,23(1):5-14.
[20] STOHLAWETZ P J,DZIRLO L,HERGOVICH N,et al.Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans[J]. Blood,2000,95(9):2983-2989.
[21] 许树根,李彩凤,沈淑琼,等. 维持性血液透析患者微炎症状态与动静脉内瘘失功的关系[J]. 临床军医杂志,2013,41(8):789-790.
[22] 熊良伟,张祥贵. 成熟自体动静脉内瘘失功的慢性危险因素研究[J]. 中国血液净化,2018,17(5):329-334.
[23] KNOLL G A,WELLS P S,YOUNG D,et al.Thrombophilia and the risk for hemodialysis vascular access thrombosis[J]. J Am Soc Nephrol,2005,16(4):1108-1114.
[24] 王葳,李泽争,韩国锋,等. 糖尿病肾病患者自体动静脉内瘘失功的相关因素分析[J]. 中国血液净化,2015,14(6):367-370.
[25] FARBER A,IMREY P B,HUBER T S,et al. Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study[J]. J Vasc Surg,2016,63(1):163-70.e6. |
